DROXIGET
Description
Hydroxyurea has constantly evolved as a drug ever since its initial approval in CML. The drug has been extensively studied in Acute Leukemias, Sickle Cell Anaemia, Nasopharyngeal Carcinoma and ovarian cancer with encouraging results. Being an immunomodulatory agent, there is documented evidence that hydroxyurea enhances anti-retroviral activity of nucleoside reverse transcriptase inhibitors (NRTIs) like abacavir and didanosine in the treatment of HIV/AIDS.
Indications:
- Head and neck carcinomas
- CML; ALL and acute nonlymphocytic leukemia with high blas counts
- Essential thrombocythemia
- Polycythemia rubra vera
- Prevantion of retinoic acid syndrome in acute promyelocytic leukemia
- Sickle cell anemia with frequent painful crises
| Generic Name | Strength | Standard | Type | Packing | Pack Size |
| Hydroxyurea | 500 mg | USP | Capsules | Strip | 1×10 |